Associations of Serum Retinol and α-Tocopherol Levels with Uric Acid Concentrations: Analysis of a Population-Based, Nationally Representative Sample

Yunkyung Kim 1,†, Jung Hee Choi 2,†, Jihun Kang 3,4,* Geun-Tae Kim 1 and Seung-Geun Lee 5

1 Division of Rheumatology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan 49104, Korea; efmsungmo@hanmail.net (Y.K.); gtah@hanmail.net (G.-T.K.)
2 Department of Anesthesiology and Pain Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju 28644, Korea; choijh0612@gmail.com
3 Department of Family Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan 49104, Korea
4 Central Institute for Medical Research, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan 49104, Korea
5 Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine & Pusan National University Hospital, Busan 49241, Korea; sglee@pnuh.co.kr
* Correspondence: josua85@naver.com; Tel.: +82-51-990-6155
† These authors equally contributed to this work.

Received: 8 May 2020; Accepted: 15 June 2020; Published: 17 June 2020

Abstract: The effects of serum retinol and α-tocopherol on serum uric acid levels have not been established, especially in Asian people. This study evaluated the independent associations of retinol and α-tocopherol with serum uric acid levels in the Korean population. We included 6023 participants aged ≥ 19 years from the Korean National Health and Nutrition Examination Survey (KNHANES). Serum retinol and α-tocopherol levels were divided into quintiles, and a multivariate linear regression model was used to evaluate the association of serum retinol and α-tocopherol levels with uric acid concentration. Additionally, we used multivariate logistic regression to examine the relationships between the levels of these micronutrients and hyperuricemia. Serum retinol levels were positively associated with uric acid concentrations in a dose-dependent fashion in both sexes (p_trend < 0.001); the difference in serum uric acid levels between the highest and lowest quintiles of retinol levels was 0.57 mg/dL in men and 0.54 mg/dL in women. In the multivariable logistic model, the hyperuricemia risk increased linearly with the increase in serum retinol level, regardless of sex (p_trend < 0.001). Although the serum α-tocopherol level appeared to be significantly associated with increased uric acid levels, this association was nullified after adjusting for serum retinol levels. Serum retinol levels were positively associated with serum uric acid levels and hyperuricemia in a dose-response fashion. Maintaining serum retinol concentrations under sub-toxic levels might be necessary to prevent hyperuricemia-related adverse health outcomes.

Keywords: retinol; α-tocopherol; uric acid; hyperuricemia; gout; KNHANES

1. Introduction

Hyperuricemia is not only a main risk factor for gout [1] but is also an independent determinant of type 2 diabetes [2], hypertension [3], metabolic syndrome [4], and chronic kidney disease [5]. Elevated serum uric acid is reported to be associated with an increased risk of non-dipping blood pressure [6], myocardial infarction [7], and cardiovascular mortality [7]. Serum uric acid levels may
increase due to heavy alcohol consumption [8], high purine diet [9], impaired renal or extra-renal excretion [10], and increased cell turnover [11]. The prevalence of hyperuricemia is increasing worldwide. Approximately 21% of the US population had hyperuricemia in the 2007–2008 National Health and Nutrition Examination Survey (NHANES), a rate 3.2% higher than that in the 1988–1994 NHANES [12]; meanwhile, a 4.3% increase in prevalence was observed in Italy within 4 years (2005–2009) [13]. In Korea, although the prevalence of hyperuricemia was 11.4%, hyperuricemia was especially prevalent in young adults [14].

Vitamin A is an essential component for fetal growth, vision, and immune response [15], and deficiency of this micronutrient is associated with vision problems [16] and an increased risk of infection [17]. However, in developed countries where the consumption of vitamin A exceeds the Recommended Dietary Allowance (RDA) in a significant number of individuals [18], the toxic or sub-toxic effects of excessive vitamin A are perceived as a public health issue [19]. Regarding serum uric acid levels, synthetic vitamin A used for the treatment of acne was reported to have negative impacts on the development of hyperuricemia [20] and gout [21]. In addition, two population-based studies in the US reported that serum retinol concentration was independently associated with hyperuricemia [22,23], and a study on adolescents in the US also showed that uric acid levels were elevated in association with serum retinol and retinyl ester concentrations [24].

As an antioxidant and anti-inflammatory nutrient, α-tocopherol protects cells from free-radical damage [15] and is associated with a decreased risk of prostate cancer [25]. However, vitamin E supplementation can increase the risk of brain hemorrhage as well as overall mortality [26,27]. Limited studies have been conducted on the effects of α-tocopherol on serum uric acid levels, and the results were inconsistent. An experimental study on rats showed that vitamin E was associated with decreased serum uric acid levels [28]. In contrast, a study on chronic kidney disease patients observed no significant association between serum vitamin E and uric acid levels [29].

Despite previous research, the effects of serum retinol and α-tocopherol on uric acid concentrations have not been established, especially in Asian populations. Furthermore, compared to studies evaluating these micronutrients using food frequency questionnaires, relatively few studies have assessed serum retinol and α-tocopherol levels. Therefore, this study aimed to evaluate the association of serum retinol and α-tocopherol levels with hyperuricemia in the general Korean population.

2. Materials and Methods

2.1. Study Population

This study used data from the Korea National Health and Nutritional Examination Survey (KNHANES). The survey is described in detail elsewhere [30]. Briefly, the KNHANES is a nationally representative study that collects data on non-institutionalized South Korean citizens that is conducted annually by the Korean Center for Disease Control and Prevention (KCDC, Chongzhou, Korea). This survey comprises a health interview, health examination, and nutritional survey and uses stratified, multi-stage, clustered probability sampling to obtain a nationally representative sample.

We used data from KNHANES 2016–2018, which included measurements of serum retinol, α-tocopherol, and uric acid levels. Among 31,689 eligible individuals, 24,269 participated in the survey, corresponding to a response rate of 76.6%; of these respondents, serum retinol and α-tocopherol levels were measured in 7189 randomly selected participants. Among them, 6424 participants aged ≥ 19 years with available information on retinol and α-tocopherol concentrations and serum uric acid levels were identified. Additionally, 401 participants were excluded for the following reasons: previous diagnosis of renal cell carcinoma (n = 10); pregnancy (n = 20); glomerular filtration rate (GFR) < 10 mL/min/1.73 m² (n = 5); outliers of serum retinol (n = 1 [2.27 mg/L]) or α-tocopherol (n = 2 [95 and 140 mg/L, respectively]) values; or missing data on anthropometric variables (body mass index [BMI, n = 12], blood pressure [n = 13]), education level (n = 25), alcohol consumption (n = 44), smoking
The study protocol was approved by the Kosin University Gospel Hospital Institutional Review Board (IRB, No. KUGH 2020-IRB 2020-03-053) and complied with the tenets of the Declaration of Helsinki. All study procedures also complied with Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines, and written informed consent was obtained from all participants.

2.2. Data Collection and Measurement

Trained research assistants collected information on sociodemographic variables (age, sex, area of residence, and education) during face-to-face interviews. Data regarding health behaviors (alcohol consumption, smoking status, and physical activity) were obtained from self-administered questionnaires. Residential areas were categorized as rural or urban, and education level was categorized as elementary school, middle school, high school, or university or above. Alcohol consumption was defined as ≥7 and ≥5 drinks on an occasion in men and women, respectively, and further categorized into no drinks, less than once per week, and more than or equal to once per week. Based on the World Health Organization (WHO) criteria, smoking status was categorized into non, past, and current smokers. Participants who engaged in moderate physical activity for ≥150 min per week or in vigorous activity ≥75 min per week were defined as physically active according to WHO global recommendations [31] and were dichotomously categorized.

Trained medical assistants assessed weight, height, and blood pressure in the specially designed mobile center for physical examinations. Height (kg, SECA, Hamburg, Germany) and weight (m, GL-6000-20, Daegu, Korea) were measured while participants wore light clothing without shoes; BMI was calculated as the weight divided by the square of the height. Blood pressure was measured thrice using a mercury sphygmomanometer (Baum, Sidney, OH, USA) and stethoscope (3M, St. Paul, MN, USA) after participants had rested for 5 min. The mean of the latter two blood pressure values was used, regardless of the first measured value.

Venous blood samples were drawn through venipuncture using a vacutainer needle and tubes. Once serum was separated, laboratory tests were performed to measure serum retinol, α-tocopherol, uric acid, creatinine, and CRP levels. Serum retinol and α-tocopherol levels were measured by liquid chromatography–flame ionization (Agilent1200, Agilent, Santa Clara, CA, USA) with reference ranges of 0.30–0.70 mg/L and 5.00–20.00 mg/L, respectively. Kinetic Jaffe assays (Hitachi automatic analyzer 7600–210, Tokyo, Japan) were used to measure serum creatinine levels, and the GFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Immunoturbidimetry was used to measure hs-CRP levels (Cobas, Roche, Germany). Serum uric acid levels were assessed by colorimetry with a uricase-catalase system (Hitachi automatic analyzer 7600–210, Tokyo, Japan). Hyperuricemia was defined as a serum urate level >7.0 mg/dL in men and >6.0 mg/dL in women.

2.3. Statistical Analysis

The KNHANES constructed a sampling plan using a multistage clustered probability design to obtain nationally representative data. Based on census data, sample weights were generated to address the complex survey design, post-stratification data, and non-responders. Therefore, all analyses used the complex survey design and sample weights.

We compared the general characteristics of the study participants according to hyperuricemia status. For normally distributed continuous variables, chi-squared tests were performed to assess normally distributed continuous variables and categorical variables. As the hs-CRP values were not normally distributed, we performed comparisons using Mann–Whitney U-tests.

Because fortified foods and dietary supplements commonly contain both vitamins A and E, we used Pearson correlation coefficients to explore the correlations between serum retinol and α-tocopherol levels. In addition, we used a general linear regression model to evaluate the association of retinol
and α-tocopherol concentrations with serum uric acid levels. We included variables with $p < 0.1$ in the univariate analysis or with significant associations with uric acid (as reported in previous studies) as covariates. Model 1 was adjusted for age; Model 2 was additionally adjusted for BMI and GFR; Model 3 was additionally adjusted for area of residence, education level, systolic and diastolic blood pressure, alcohol consumption, smoking status, and physical activity; Model 4 was additionally and mutually adjusted for serum retinol and α-tocopherol levels. Quintile distributions of serum retinol and α-tocopherol levels were inserted in the analysis models as continuous variables to estimate the dose-dependent relationship between serum micronutrient and uric acid levels, with the lowest quintile set as the reference value for comparisons. In addition, we conducted a subgroup analysis of the association between dietary retinol intake and serum uric acid levels among participants with dietary information obtained using a 24-h dietary recall method.

We conducted multivariate logistic analysis to estimate the risk of hyperuricemia in relation to retinol and α-tocopherol levels after adjusting for the mentioned covariates. The $p$-values for trends were calculated to examine whether the risk of hyperuricemia increased with higher serum micronutrient levels.

In addition, a sensitivity analysis was conducted to assess whether the use of dietary supplements modified the association between micronutrients and hyperuricemia. The effects of stratification were determined by inserting an interaction term of dietary supplement use in the final multivariate logistic analysis.

All tests were two-tailed, and $p$-values < 0.05 were considered statistically significant. All analyses were performed using IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY, USA).

3. Results

3.1. General Characteristics of Study Participants

The prevalence of hyperuricemia was 18.5% in men and 5.7% in women. The mean serum retinol and α-tocopherol levels were higher in hyperuricemia participants than in non-hyperuricemia participants. While men with hyperuricemia were younger, the mean age of women with hyperuricemia was higher than that of women without hyperuricemia. Education level, BMI, systolic and diastolic blood pressure, and hs-CRP levels were higher in the hyperuricemia group than in the non-hyperuricemia group for both sexes. Female participants with hyperuricemia were more likely to be current smokers and to have lower GFR than women without hyperuricemia (Table 1).

3.2. Correlation between Serum Retinol and α-Tocopherol

The inter-relationships between serum retinol and α-tocopherol levels are presented in Figure 1. Serum retinol was positively correlated with α-tocopherol ($r^2 = 0.123$, $p < 0.001$ in men and $r^2 = 0.136$, $p < 0.001$ in women).

![Figure 1. Correlation between serum retinol and α-tocopherol levels. Data are presented as scatter plots with lines of best fit.](image-url)
Table 1. General characteristics of study population.

|                                | Hyperuricemia (N = 472) | No Hyperuricemia (N = 2250) | p-Value | Hyperuricemia (N = 193) | No Hyperuricemia (N = 3108) | p-Value |
|--------------------------------|--------------------------|-----------------------------|---------|-------------------------|-----------------------------|---------|
| **Age, mean (SE)**             | 40.2 (0.7)               | 45.8 (0.4)                  | <0.001  | 49.7 (1.6)              | 46.0 (0.3)                  | 0.022   |
| **Area of residence, % (SE)**  |                          |                             |         |                         |                             |         |
| Urban                          | 86.3 (2.2)               | 86.6 (1.5)                  | 0.838   | 83.2 (3.4)              | 86.1 (1.5)                  | 0.318   |
| Rural                          | 13.7 (2.2)               | 13.4 (1.5)                  |         | 16.8 (3.4)              | 13.9 (1.5)                  |         |
| **Education, % (SE)**          |                          |                             |         |                         |                             |         |
| Elementary school              | 4.4 (0.8)                | 9.1 (0.6)                   | 0.028   | 22.7 (3.3)              | 15.5 (0.7)                  | 0.040   |
| Middle school                  | 7.5 (1.3)                | 7.5 (0.6)                   |         | 11.0 (2.2)              | 9.0 (0.5)                   |         |
| High school                    | 39.8 (2.8)               | 36.9 (1.2)                  |         | 34.9 (4.0)              | 34.3 (1.0)                  |         |
| University or above            | 48.2 (2.9)               | 46.6 (1.3)                  |         | 31.5 (4.4)              | 41.2 (1.1)                  |         |
| **Smoking status**             |                          |                             |         |                         |                             |         |
| Non-smokers                    | 32.3 (2.6)               | 29.4 (1.1)                  | 0.413   | 86.4 (2.7)              | 89.0 (0.7)                  | 0.016   |
| Past smokers                   | 29.8 (2.3)               | 33.1 (1.1)                  |         | 2.9 (1.1)               | 5.1 (0.9)                   |         |
| Current smokers                | 37.9 (2.6)               | 37.5 (1.3)                  |         | 10.7 (2.6)              | 5.8 (0.5)                   |         |
| **Alcohol consumption, % (SE)**|                          |                             |         |                         |                             |         |
| None                           | 25.2 (2.3)               | 31.0 (1.1)                  | 0.090   | 64.9 (3.9)              | 59.2 (1.1)                  | 0.171   |
| <1/week                        | 36.6 (2.8)               | 35.1 (1.2)                  |         | 23.2 (3.8)              | 30.6 (1.0)                  |         |
| ≥1/week                        | 38.2 (2.6)               | 34.0 (1.2)                  |         | 11.9 (2.5)              | 10.2 (0.7)                  |         |
| **Physical activity, % (SE)**  |                          |                             |         |                         |                             |         |
| No                             | 48.3 (2.7)               | 47.9 (1.2)                  | 0.897   | 53.0 (4.2)              | 54.6 (1.1)                  | 0.657   |
| Yes                            | 51.7 (2.7)               | 52.1 (1.2)                  |         | 47.0 (4.2)              | 45.2 (1.1)                  |         |
| **Body mass index, % (SE)**    |                          |                             |         |                         |                             |         |
| <25                            | 26.1 (0.2)               | 24.2 (0.1)                  | <0.001  | 26.3 (0.4)              | 23.1 (0.1)                  | <0.001  |
| ≥25                            | 121.6 (0.7)              | 119.1 (0.4)                 | <0.001  | 120.1 (2.0)             | 114.0 (0.3)                 | 0.002   |
| **Systolic blood pressure, mmHg** | 81.2 (0.5)               | 78.0 (0.5)                  | <0.001  | 75.3 (0.9)              | 73.4 (0.2)                  | 0.037   |
| **Diastolic blood pressure, mmHg** | 94.1 (0.9)               | 96.8 (0.4)                  | 0.161   | 89.7 (2.0)              | 102.1 (0.3)                 | <0.001  |
| **GFR, ml/min/1.73m²**         |                          |                             |         |                         |                             |         |
| Medicinal (IQR)                | 0.8 (0.5,1.6)            | 0.5 (0.3,0.98)              | <0.001  | 0.78 (0.48,1.53)        | 0.55 (0.35,1.04)            | <0.001  |
| **Urinary acid, mg/dL**        |                          |                             |         | 0.50 (0.02)             | 0.001                      | <0.001  |
| Serum creatinine, mg/dL        | 7.64 (0.04)              | 4.86 (0.02)                 | 0.001   | 7.89 (0.04)             | 4.86 (0.02)                 | 0.001   |
| Serum retinol, mg/L            | 0.61 (0.01)              | 0.51 (0.01)                 | <0.001  | 0.63 (0.01)             | 0.57 (0.01)                 | <0.001  |
| Serum α-tocopherol, mg/L       | 14.1 (0.3)               | 13.3 (0.1)                  | 0.006   | 14.0 (0.3)              | 13.1 (0.1)                  | 0.008   |

Data are presented as weighted percentages (standard error [SE]) or weighted means (SE) unless otherwise stated. p-values were calculated with the use of a chi-squared test for categorical variables, a Student's t-test for continuous variables, and a Mann–Whitney U-test for non-normally distributed variables, respectively. Hyperuricemia was defined as serum urate level >7.0 mg/dL and >6.0 mg/dL in men and women, respectively. * Smoking status was categorized based on World Health Organization (WHO) criteria. † Alcohol consumption was defined as ≥7 drinks in men and ≥5 drinks in women on an occasion. ‡ Physical activity was defined as ≥150 min of moderate activity per day or ≥75 min of vigorous activity per day based on the WHO recommendation.
3.3. Association of Serum Retinol and α-Tocopherol Concentration with Uric Acid Levels

Uric acid levels steadily increased with higher serum retinol levels (from 5.61 mg/dL in the lowest retinol quintile [Q1] to 6.27 mg/dL in the highest quintile [Q5] in men and from 4.25 mg/dL in Q1 to 4.96 mg/dL in Q5 in women) after adjusting for age (p_trend < 0.001 in both sexes). In fully adjusted analyses, the difference in serum uric acid levels across quintiles of retinol was slightly reduced, from 0.66 mg/dL to 0.57 mg/dL in men and from 0.71 mg/dL to 0.54 mg/dL in women, but remained significant. Although serum α-tocopherol levels were positively associated with serum uric acid levels from Models 1 to 3, the association was not significant after adjusting for serum retinol levels (Table 2). Therefore, there was no association between the dietary intake of retinol and serum uric acid level in both sexes (Supplementary Table S1).

Table 2. Association of serum retinol and α-tocopherol concentration with uric acid levels.

|               | Q1   | Q2   | Q3   | Q4   | Q5   | p_trend *
|---------------|------|------|------|------|------|----------
| **Men**       |      |      |      |      |      |          |
| Retinol       |      |      |      |      |      |          |
| Model 1 *     | 5.61 (5.50,5.73) | 5.79 (5.67,5.91) | 6.01 (5.89,6.13) | 6.09 (5.96,6.22) | 6.27 (6.14,6.40) | <0.001   |
| Model 2 †     | 5.70 (5.59,5.80) | 5.83 (5.71,5.94) | 6.02 (5.91,6.12) | 6.03 (5.90,6.15) | 6.19 (6.06,6.32) | <0.001   |
| Model 3 ‡     | 5.67 (5.54,5.80) | 5.85 (5.71,5.99) | 6.05 (5.92,6.19) | 6.08 (5.94,6.23) | 6.24 (6.09,6.39) | <0.001   |
| Model 4 §     | 5.67 (5.53,5.80) | 5.85 (5.71,5.99) | 6.05 (5.92,6.19) | 6.08 (5.94,6.23) | 6.24 (6.09,6.40) | <0.001   |
| α-tocopherol  |      |      |      |      |      |          |
| Model 1 *     | 5.78 (5.66,5.90) | 5.84 (5.73,5.96) | 5.98 (5.86,6.10) | 6.09 (5.95,6.22) | 6.05 (5.91,6.18) | <0.001   |
| Model 2 †     | 5.86 (5.75,5.98) | 5.87 (5.77,5.98) | 5.97 (5.86,6.08) | 6.03 (5.90,6.17) | 5.99 (5.86,6.11) | 0.034    |
| Model 3 ‡     | 5.90 (5.76,6.04) | 5.91 (5.76,6.03) | 5.99 (5.86,6.12) | 6.06 (5.90,6.21) | 6.00 (5.85,6.15) | 0.097    |
| Model 4 §     | 6.00 (5.86,6.15) | 5.93 (5.81,6.06) | 6.00 (5.87,6.13) | 6.02 (5.87,6.17) | 5.90 (5.75,6.06) | 0.549    |
| **Women**     |      |      |      |      |      |          |
| Retinol       |      |      |      |      |      |          |
| Model 1 *     | 4.25 (4.19,4.30) | 4.38 (4.30,4.45) | 4.59 (4.49,4.70) | 4.74 (4.60,4.87) | 4.96 (4.77,5.14) | <0.001   |
| Model 2 †     | 4.28 (4.23,4.33) | 4.37 (4.30,4.45) | 4.56 (4.46,4.66) | 4.68 (4.55,4.80) | 4.83 (4.67,4.99) | <0.001   |
| Model 3 ‡     | 4.35 (4.24,4.45) | 4.44 (4.34,4.54) | 4.63 (4.51,4.76) | 4.75 (4.61,4.88) | 4.89 (4.72,5.06) | <0.001   |
| Model 4 §     | 4.35 (4.25,4.45) | 4.45 (4.35,4.55) | 4.63 (4.51,4.76) | 4.75 (4.61,4.88) | 4.89 (4.72,5.07) | <0.001   |
| α-tocopherol  |      |      |      |      |      |          |
| Model 1 *     | 4.30 (4.21,4.39) | 4.36 (4.27,4.44) | 4.38 (4.30,4.47) | 4.48 (4.39,4.57) | 4.56 (4.47,4.65) | <0.001   |
| Model 2 †     | 4.33 (4.25,4.41) | 4.36 (4.28,4.45) | 4.41 (4.33,4.49) | 4.46 (4.37,4.54) | 4.51 (4.43,4.60) | 0.001    |
| Model 3 ‡     | 4.45 (4.33,4.56) | 4.50 (4.39,4.61) | 4.53 (4.41,4.64) | 4.57 (4.46,4.68) | 4.61 (4.49,4.72) | 0.006    |
| Model 4 §     | 4.46 (4.35,4.57) | 4.48 (4.37,4.59) | 4.48 (4.36,4.60) | 4.49 (4.38,4.60) | 4.47 (4.34,4.59) | 0.996    |

Data are presented with mean (standard error). *p-values for trend were calculated using linear regression analysis by considering quintile distribution of serum retinol and α-tocopherol levels as continuous variables. † Model 1 adjusted for age; ‡ Model 2 additionally adjusted for body mass index (BMI) and glomerular filtration rate (GFR); § Model 3 additionally adjusted for residence, education, smoking status, alcohol consumption, physical activity, systolic and diastolic blood pressure, and log transformed high sensitivity C-reactive protein (hs-CRP); Model 4 additionally adjusted for serum retinol and α-tocopherol levels mutually.

3.4. Association between Serum Retinol and α-Tocopherol Levels and Hyperuricemia

In the multivariable logistic regression model, the risk of hyperuricemia increased with the increase in serum retinol and α-tocopherol levels (p_trend < 0.001 in both sexes). The odds ratio (OR) for hyperuricemia in Q5, compared to Q1 of retinol levels, was 3.37 in men and 3.95 in women. The concentration of α-tocopherol showed a tendency to increase the risk of hyperuricemia.
in the age-adjusted analysis; however, the association disappeared after adjusting for serum retinol levels (Figure 2).

Figure 2. Association of serum retinol and α-tocopherol levels with hyperuricemia. Data are presented as odds ratio with 95% confidence intervals (error bars).

3.5. Interactive Effects of Dietary Supplements and Serum Retinol and α-Tocopherol on Hyperuricemia

Our analysis exploring the potential interactive effect of dietary supplementation on the association between micronutrients and hyperuricemia showed no significant interaction, except for serum retinol levels in women ($p_{\text{interaction}} = 0.012$). While the magnitude of the association between serum retinol levels and the risk of hyperuricemia increased in women taking dietary supplements, the strength of the association decreased in men taking dietary supplements (Table 3).
Table 3. Use of dietary supplements stratified association of serum retinol and α-tocopherol concentration with hyperuricemia ‡.

|                      | Q1     | Q2     | Q3     | Q4     | Q5     | p_trend * | p_interaction † |
|----------------------|--------|--------|--------|--------|--------|-----------|-----------------|
| Total Retinol        |        |        |        |        |        |           |                 |
| Dietary supplements  | Reference  | 0.72 (0.37,1.39) | 1.17 (0.59,2.33) | 1.91 (0.97,3.73) | 2.24 (1.13,4.45) | <0.001   | 0.617         |
| No dietary supplements | Reference  | 1.13 (0.66,1.96) | 2.13 (1.26,3.61) | 2.48 (1.42,4.31) | 3.89 (2.25,6.74) | <0.001   |
| α-tocopherol         |        |        |        |        |        |           |                 |
| Dietary supplements  | Reference  | 1.02 (0.55,1.90) | 1.01 (0.55,1.86) | 0.71 (0.38,1.32) | 1.29 (0.72,2.30) | 0.622   | 0.295         |
| No dietary supplements | Reference  | 0.90 (0.58,1.40) | 1.04 (0.67,1.61) | 1.18 (0.76,1.85) | 1.00 (0.65,1.53) | 0.565   |
| Men Retinol          |        |        |        |        |        |           |                 |
| Dietary supplements  | Reference  | 1.02 (0.38,2.70) | 2.34 (0.91,6.00) | 1.68 (0.65,4.43) | 2.31 (0.90,5.95) | 0.033   | 0.604         |
| No dietary supplements | Reference  | 1.67 (0.96,2.92) | 2.37 (1.37,4.10) | 3.16 (1.78,5.62) | 3.93 (2.16,7.14) | <0.001  |
| α-tocopherol         |        |        |        |        |        |           |                 |
| Dietary supplements  | Reference  | 0.67 (0.30,1.51) | 0.98 (0.44,2.18) | 0.98 (0.47,2.08) | 1.31 (0.62,2.77) | 0.247   | 0.764         |
| No dietary supplements | Reference  | 0.96 (0.57,1.61) | 1.24 (0.73,2.10) | 1.33 (0.78,2.26) | 1.09 (0.65,1.82) | 0.373   |
| Women Retinol        |        |        |        |        |        |           |                 |
| Dietary supplements  | Reference  | 0.37 (0.15,0.96) | 1.26 (0.53,3.00) | 4.36 (1.87,10.15) | 5.61 (2.06,15.32) | <0.001  | 0.012         |
| No dietary supplements | Reference  | 1.46 (0.71,2.98) | 3.77 (1.78,7.97) | 2.19 (0.79,6.09) | 3.45 (1.53,7.75) | 0.001   |
| α-tocopherol         |        |        |        |        |        |           |                 |
| Dietary supplements  | Reference  | 0.85 (0.30,2.40) | 0.61 (0.22,1.70) | 0.28 (0.08,1.01) | 0.66 (0.22,1.97) | 0.255   | 0.618         |
| No dietary supplements | Reference  | 0.79 (0.37,1.68) | 0.64 (0.30,1.38) | 0.82 (0.35,1.92) | 0.90 (0.43,1.88) | 0.837   |

Data are presented with means (standard errors). * p-values for trend were calculated using logistic regression analysis by considering quintile distribution of serum retinol and α-tocopherol levels as continuous variables. † p-values for trend were calculated using regression analysis by inserting an interaction term for use of dietary supplements and serum retinol and α-tocopherol in the analysis. ‡ Multivariate logistic regression analysis was used with adjustment for age, residence, education, smoking status, alcohol consumption, physical activity, BMI, GFR, systolic and diastolic blood pressure, and log transformed hs-CRP serum retinol and α-tocopherol levels mutually.
4. Discussion

This nationally representative study showed that serum retinol levels were positively associated with elevated serum uric acid concentrations in a dose-responsive fashion. In addition, the risk of hyperuricemia increased linearly with increasing serum retinol levels. Serum retinol and α-tocopherol levels showed significant correlations with each other, and the serum retinol level was a confounding factor affecting the relationship between α-tocopherol and serum uric acid levels. The major strengths of the present study are (1) its nationally representative sample that provides sufficient statistical power and representativeness; (2) robust adjustment for potential compounds related to serum uric acid levels; and (3) reliable measurements of micronutrients using participants’ serum samples.

The results of the current study suggested that serum retinol levels had a dose-dependent association with serum uric acid levels and the risk of hyperuricemia, consistent with the findings of two studies conducted in the US [22,23] which reported that serum uric acid levels increased with increasing retinol concentrations. The differences in uric acid levels between the highest and lowest quintiles of retinol levels were 0.70 and 0.48 mg/dL in the 1998–1994 [22] and 2001–2006 NHANES, respectively [23]. The magnitude of difference in uric acid levels in our study was 0.57 mg/dL in men and 0.54 mg/dL in women; these values are between those reported by the two previous studies in the US. When we translated our observed findings to clinical practice, the difference in uric acid levels between the top and bottom quintiles of retinol concentrations was higher than the increase in uric acid concentrations among individuals who consumed ≥1 shot of liquor/day (0.26 mg/dL) and comparable to the increase in uric acid levels among individuals drinking ≥1 beer/day (0.42 mg/dL) [8]; however, direct comparisons are limited due to heterogeneities in the study design and measurement methods. Furthermore, a study on adolescents in the US reported positive associations of serum retinol and retinyl ester levels with uric acid concentration, which partially support our findings [24].

Hyperuricemia increased with increasing serum retinol levels, indicating that the consumption of vitamin A exceeding the recommended values from fortified foods and supplements could be responsible for adverse health outcomes related to hyperuricemia, including not only gout [1] but also hypertension [3], metabolic syndrome [4], chronic kidney disease [5], and myocardial infarction [7]. Previous studies have shown that high serum retinol levels had a negative effect on the development of osteoporosis and hip fractures [32,33]. In addition, the dietary supplementation of vitamin A significantly increased mortality [26]. Thus, dietary modification to maintain serum vitamin A at adequate but not excessive levels and the individualized use of dietary supplements might be necessary to prevent vitamin A overconsumption, not only in individuals with these health conditions, but also in the general population.

Although the use of dietary supplements strengthened the association between serum retinol levels and the risk of hyperuricemia in women, this effect was not observed in men. It is difficult to explain the effect modification of dietary supplements on hyperuricemia observed only in women; however, the higher use of the supplements in women (49.1%) than in men (37.5%) might be related to this finding. In addition, varying compositions and types of supplements according to sex could play a role in the intensified association between retinol and uric acid levels only in women [34].

Regarding the effect of α-tocopherol levels on serum uric acid levels, this study did not show any beneficial effect of α-tocopherol on the risk of hyperuricemia. Although vitamin E supplementation was shown to exhibit significant uricosuric effects and to decrease serum uric acid levels in an experimental study on rats [28], another clinical study on chronic kidney patients did not report a significant association between vitamin E and serum uric acid levels [29]. Notably, before adjusting for serum retinol levels, vitamin E levels appeared to be significantly associated with increased serum uric acid levels. However, this significant association was nullified after adjusting for serum retinol levels. This finding suggested that retinol levels could be a significant compounding factor in the analysis of α-tocopherol levels and hyperuricemia. The concomitant fortification of vitamin A and vitamin E in foods and supplements might be a plausible mechanism underlying this compounding effect [35]. Furthermore, a sex-based difference was observed in this association. Only in males did the strength of
the association between serum α-tocopherol and uric acid level disappear before adjusting for serum retinol levels. This could be hypothesized as follows: One possible explanation is that the presence of metabolic impairments in males due to smoking, increased alcohol consumption, and high blood pressure could have influenced serum uric acid levels. Another possible explanation is that estrogen’s protective role against hyperuricemia might be attributable to this mitigated degree of association observed only in males [36]. Nonetheless, further interventional studies are needed to elucidate the mechanisms underlying the observed findings.

The mechanism underlying the relationship between serum retinol levels and hyperuricemia is not yet fully understood. One possible explanation is that increased xanthine oxidase activity resulting from high serum retinol levels plays an important role in elevating serum uric acid levels. Xanthine oxidase converts retinol to retinoic acid [37] and catalyzes xanthine oxidation to produce uric acid [38]. Increased xanthine oxidase activity induced by high serum retinol levels could cause hyperuricemia by facilitating uric acid synthesis. In addition, other factors concurrently linked to high serum retinol levels and hyperuricemia, such as obesity and the intake of high-fat foods, might contribute to these two conditions [39]. However, the independent association between retinol levels and hyperuricemia remained after adjusting for these potential compounding factors in the analysis.

This study has several limitations. First, as the cross-sectional design could not address temporality issues, caution is needed when interpreting the results. In addition, although it is more likely that serum retinol levels affected serum uric acid levels, we could not exclude the possibility of reverse causality. Second, the use of uric acid-lowering medications, such as febuxostat, allopurinol, or rasburicase, was not evaluated due to data unavailability; hence, the rate of hyperuricemia might have been underestimated. However, given the prevalence of gout in South Korea (0.76%) [40], it seems unlikely that the use of these medications significantly affected our study results. Third, we could not include dietary factors other than alcohol consumption in the analysis due to the low response rate to the food intake frequency questionnaire.

Fourth, other potential factors, such as serum vitamin D and parathyroid hormone (PTH) levels, were not included in the analysis because the KNHANES 2016–2018 did not measure these variables. Fifth, when compared with serum uric acid levels, serum retinol would not be a better indicator to monitor adverse health conditions, such as hypertension, chronic kidney disease, and metabolic syndrome, owing to cost effectiveness. Finally, because the liver is the main reservoir of vitamin A, serum retinol levels might not reflect excessive vitamin A states in the human body [41].

5. Conclusions

Serum retinol levels were positively associated with serum uric acid levels and hyperuricemia in a dose-response fashion. Maintaining serum retinol concentrations under sub-toxic levels might be an effective strategy to prevent adverse health outcomes related to hyperuricemia. Further studies are warranted to confirm and elucidate the observed associations.

Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/6/1797/s1, Table S1: Association of vitamin A intake with uric acid levels.

Author Contributions: Conceptualization, Y.K., J.H.C. and J.K.; methodology, Y.K., J.H.C. and J.K.; software, Y.K., and J.K.; validation, Y.K., J.H.C., G.-T.K., S.-G.L. and J.K.; formal analysis, Y.K., and J.K.; investigation, Y.K., J.H.C. and J.K.; resources, Y.K., J.H.C. and J.K.; data curation Y.K., J.H.C. and J.K.; writing—original draft preparation, Y.K., and J.H.C.; writing—review and editing, J.K.; visualization, J.K.; supervision, J.K., G.-T.K., S.-G.L.; funding acquisition, J.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2019R1G1A1099627) and The APC was funded by NRF.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Kuo, C.-F.; Grainge, M.J.; Zhang, W.; Doherty, M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 2015, 11, 649. [CrossRef]
2. Dehghan, A.; Van Hoek, M.; Sijbrands, E.J.; Hofman, A.; Witteman, J.C. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008, 31, 361–362. [CrossRef]
3. Johnson, R.J.; Kang, D.-H.; Feig, D.; Kivlighn, S.; Kanellis, J.; Watanabe, S.; Tuttle, K.R.; Rodriguez-Iturbe, B.; Herrera-Acosta, J.; Mazzali, M. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003, 41, 1183–1190. [CrossRef]
4. Onat, A.; Uyarel, H.; Hergenc, G.; Karabulut, A.; Albayrak, S.; Sarı, I.; Yazıcı, M.; Keleş, I. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am. J. Hypertens. 2006, 19, 1055–1062. [CrossRef] [PubMed]
5. Madero, M.; Sarnak, M.J.; Wang, X.; Greene, T.; Beck, G.J.; Kusek, J.W.; Collins, A.J.; Levey, A.S.; Menon, V. Uric acid and long-term outcomes in CKD. Am. J. Kidney Dis. 2009, 53, 796–803. [CrossRef] [PubMed]
6. Afsar, B.; Elsurer, R.; Özdemir, F.N.; Sezer, S. Uric acid and nocturnal nondipping in hypertensive patients with normal renal function. J. Nephrol. 2008, 21, 406–411.
7. Maloberti, A.; Giannattasio, C.; Bombelli, M.; Desideri, G.; Cicero, A.; Muiñes, M.; Rosei, E.; Salvetti, M.; Ungar, A.; Rivasi, G. Hyperuricemia and risk of cardiovascular outcomes: The experience of the URRAH (Uric Acid Right for Heart Health) project. High Blood Press. Cardiovasc. Prev. 2020, 21, 121–128. [CrossRef] [PubMed]
8. Choi, H.K.; Curhan, G. Beer, liquor, and wine consumption and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004, 51, 1023–1029. [CrossRef]
9. Choi, H.K.; Atkinson, K.; Karlson, E.W.; Willett, W.; Curhan, G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med. 2004, 350, 1093–1103. [CrossRef]
10. Ichida, K.; Matsuoka, H.; Takada, T.; Nakayama, A.; Murakami, K.; Shimizu, T.; Yamanashi, Y.; Kasuga, H.; Nakashima, H.; Nakamura, T. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 2012, 3, 1–7. [CrossRef] [PubMed]
11. Davidson, M.B.; Thakkar, S.; Hix, J.K.; Bhandarkar, N.D.; Wong, A.; Schreiber, M.J. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am. J. Med. 2004, 116, 546–554. [CrossRef] [PubMed]
12. Zhu, Y.; Pandya, B.J.; Choi, H.K. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011, 63, 3136–3141. [CrossRef]
13. Trifiro, G.; Morabito, P.; Cavagna, L.; Ferrajolo, C.; Pecchioli, S.; Simonetti, M.; Bianchini, E.; Medea, G.; Cricielli, C.; Caputi, A.P.; et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: A nationwide population-based study. Ann. Rheum. Dis. 2013, 72, 694–700. [CrossRef] [PubMed]
14. Kim, Y.; Kang, J.; Kim, G.-T. Prevalence of hyperuricemia and its associated factors in the general Korean population: An analysis of a population-based nationally representative sample. Clin. Rheumatol. 2018, 37, 2529–2538. [CrossRef] [PubMed]
15. Shils, M.E.; Shike, M. Modern Nutrition in Health and Disease; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2006.
16. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001, 119, 1417–1436. [CrossRef] [PubMed]
17. Huiming, Y.; Chaomin, W.; Meng, M. Vitamin A for treating measles in children. Cochrane Database Syst. Rev. 2005, 4, CD001479.
18. Kang, M.; Kim, D.; Baek, Y.; Moon, S.; Jung, H.; Song, Y.; Paik, H. Dietary supplement use and its effect on nutrient intake in Korean adult population in the Korea National Health and Nutrition Examination Survey IV (2007–2009) data. Eur. J. Clin. Nutr. 2014, 68, 804–810. [CrossRef] [PubMed]
19. Penniston, K.L.; Tanumihardjo, S.A. The acute and chronic toxic effects of vitamin A. Am. J. Clin. Nutr. 2006, 83, 191–201. [CrossRef]
20. Solak, B.; Erdem, T.; Solak, Y. Isotretinoin use for acne vulgaris is associated with increased serum uric acid levels. J. Dermatol. Treat. 2017, 28, 82–85. [CrossRef]
21. Vanhootegehem, O.; André, J.; Pochet, J.; Demaubeuge, J.; Song, M. Occurrence of gouty tophi following acitretin therapy. *Clin. Exp. Derm.* 1998, 23, 274–276. [CrossRef]  
22. Choi, W.J.; Ford, E.S.; Curhan, G.; Rankin, J.I.; Choi, H.K. Independent association of serum retinol and β-carotene levels with hyperuricemia: A national population study. *Arthritis Care Res. (Hoboken)* 2012, 64, 389–396. [CrossRef] [PubMed]  
23. Ford, E.S.; Choi, H.K. Associations between concentrations of uric acid with concentrations of vitamin A and beta-carotene among adults in the United States. *Nutr. Res.* 2013, 33, 995–1002. [CrossRef] [PubMed]  
24. Beydoun, M.A.; Canas, J.A.; Beydoun, H.A.; Chen, X.; Shroff, M.R.; Zonderman, A.B. Serum antioxidant concentrations and metabolic syndrome are associated among US adolescents in recent national surveys. *J. Nutr.* 2012, 142, 1693–1704. [CrossRef] [PubMed]  
25. Heinonen, O.P.; Albanes, D.; Virtamo, J.; Taylor, P.R.; Huttunen, J.K.; Hartman, A.M.; Haapakoski, J.; Malila, N.; Rautalahti, M.; Ripatti, S.; et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. *J. Natl. Cancer Inst.* 1998, 90, 440–446. [CrossRef]  
26. Bjelakovic, G.; Nikolova, D.; Ghuud, L.L.; Simonetti, R.G.; Ghuud, C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. *Jama* 2007, 297, 842–857. [CrossRef]  
27. Sesso, H.D.; Buring, J.E.; Christen, W.G.; Kurth, T.; Belanger, C.; MacFadyen, J.; Bubes, V.; Manson, J.E.; Glynn, R.J.; Gaziano, J.M. Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians’ Health Study II randomized controlled trial. *Jama* 2008, 300, 2123–2133. [CrossRef]  
28. Seifi, B.; Kadkhodaei, M.; Zahmatkesh, M. Effect of vitamin E therapy on serum uric acid in DOCA-salt-treated rats. *Acta Physiol. Hung.* 2011, 98, 214–220. [CrossRef]  
29. Kuroda, M.; Asaka, S.; Tofuku, Y.; Takeda, R. Serum antioxidant activity in uremic patients. *Acta Physiol. Hung.* 2011, 98, 221–228. [CrossRef]  
30. Kweon, S.; Kim, Y.; Jang, M.J.; Kim, Y.; Kim, K.; Choi, S.; Chun, C.; Khang, Y.H.; Oh, K. Data resource profile: The Korea National Health and Nutrition Examination Survey (KNHANES). *Int. J. Epidemiol.* 2014, 43, 69–77. [CrossRef]  
31. Armstrong, T.; Bull, F. Development of the world health organization global physical activity questionnaire (GPAQ). *J. Public Health* 2006, 14, 66–70. [CrossRef]  
32. Feskanich, D.; Singh, V.; Willett, W.C.; Colditz, G.A. Vitamin A intake and hip fractures among postmenopausal women. *Jama* 2002, 287, 47–54. [CrossRef] [PubMed]  
33. Michaëlsson, K.; Lithell, H.; Vessby, B.; Melhus, H. Serum retinol levels and the risk of fracture. *N. Engl. J. Med.* 2003, 348, 287–294. [CrossRef] [PubMed]  
34. Kim, J.; Lee, J.S.; Shin, A.; Kang, M.H.; Shin, D.S.; Chung, H.R.; Kim, W.K. Sociodemographic and lifestyle factors are associated with the use of dietary supplements in a Korean population. *J. Epidemiol.* 2010, 20, 197–203. [CrossRef]  
35. Fulgoni, V.L., 3rd; Keast, D.R.; Bailey, R.L.; Dwyer, J. Foods, fortificants, and supplements: Where do Americans get their nutrients? *J. Nutr.* 2011, 141, 1847–1854. [CrossRef]  
36. Hak, A.E.; Choi, H.K. Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey. *Arthritis Res. 2008*, 10, R116. [CrossRef] [PubMed]  
37. Taibi, G.; Nicotra, C.M. Xanthine oxidase catalyzes the oxidation of retinol. *J. Enzym. Inhib. Med. Chem.* 2007, 22, 471–476. [CrossRef]  
38. Mawson, A. Hypervitaminosis A toxicity and gout. *Lancet (Lond. Engl.)* 1984, 1, 1181. [CrossRef]  
39. Tungtrongchitr, R.; Changbumrung, S.; Tungtrongchitr, A.; Schelp, F.P. The relationships between anthropometric measurements, serum vitamin A and E concentrations and lipid profiles in overweight and obese subjects. *Asia Pac. J. Clin. Nutr.* 2003, 12, 73–79.  
40. Kim, J.-W.; Kwak, S.G.; Lee, H.; Kim, S.-K.; Choe, J.-Y.; Park, S.-H. Prevalence and incidence of gout in Korea: Data from the national health claims database 2007–2015. *Rheumatol. Int.* 2017, 37, 1499–1506. [CrossRef]  
41. Tanumihardjo, S.A. Vitamin A: Biomarkers of nutrition for development. *Am. J. Clin. Nutr.* 2011, 94, 6585–6655. [CrossRef]